Announcements · July 25, 2026 · 5 min read
The FDA just voted on 7 peptides. Here's what changed (and what didn't)
The FDA's advisory panel just voted on BPC-157 and six other peptides. Here is what happened and what it means for patients.
On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) took up a major question: whether seven of the most talked-about peptides — BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP — should move onto the approved list for compounding in the U.S. Six passed. One did not. That sounds decisive, but the reality is more nuanced.
What the committee voted
Across two days, the committee reviewed each peptide individually. BPC-157, KPV, and TB-500 each passed 8-6 with one abstention; MOTS-c passed 7-5; Semax passed 8-5; Epitalon passed 7-5; and DSIP was rejected 6-7. In total, six of seven peptides received a positive recommendation for potential compounding.
Why is this such a big deal? Because the FDA's own career scientists had recommended against all seven, citing limited safety data and gaps in chemical characterization. The committee voting against that guidance is something that does not happen often — which is why this decision is getting attention well beyond niche peptide circles.
What this does not mean (yet)
The PCAC is an advisory body. Its vote is a recommendation, not a rule change. For any of these peptides to become Category 1, the FDA has to go through formal rulemaking: publishing a proposed rule, opening a public comment period, and issuing a final rule. That process usually takes several months.
Why the vote is more complicated than it looks
Critics raised real concerns: a number of committee members were newly appointed just weeks before the meeting, some members have disclosed ties to clinics offering peptide therapies, and major organizations — including the American Pharmacies Association and the Partnership for Safe Medicines — formally opposed adding any of the seven, citing safety concerns and limited clinical data.
Supporters make an equally specific case about a different risk: the existing peptide gray market, where product purity, dosing accuracy, and contamination are unverifiable. One committee member described a patient who brought in a "research-grade" peptide that tested positive for MDMA contamination — exactly the kind of risk a licensed and monitored pathway is designed to reduce. Supporters argue a regulated compounding pathway is safer than the current alternative, and it is a strong argument.
What this means for patients
If the FDA follows the committee's recommendation, there could be a regulated, clinician-supervised pathway to BPC-157, TB-500, and the others — instead of the unverified sources people currently turn to. It is also worth noting that this vote runs in the opposite direction of GLP-1 compounding, where the FDA has moved to restrict access rather than expand it. The peptide regulatory landscape is not moving in a single direction; it is evolving case by case.
Frequently asked questions
Did the FDA approve these peptides as drugs? No. This process is about whether compounding pharmacies can legally prepare these substances for patients with a prescription — a different and much lower bar than full FDA drug approval. These peptides are not FDA-approved drugs.
What happens next? The FDA will review the committee's recommendation and decide whether to begin formal rulemaking. If it does, expect a timeline of at least six to twelve months before any change takes effect.
Demand for these peptides has already outgrown the current regulatory framework — people are seeking access whether or not a safe pathway exists. When that demand is met through unverified sources instead of licensed ones, it becomes a public safety issue, not just a compliance one. That is why we support moving peptides with reasonable evidence behind them onto the regulated pathway, and why every Rise Wellness and Longevity protocol is dispensed exclusively through licensed 503A and 503B pharmacies under physician supervision.
Sources
Adapted for Rise Wellness and Longevity from reporting originally published by Altro Health. Educational content only; not medical advice.